Appeals require meticulous attention to detail, particularly those involving intellectual property. And they demand a thorough understanding of both the law and the facts to identify the one or two arguments with the most promise to persuade a panel of appellate jurists. Finnegan is widely known for the quality of its appellate briefs and oral advocacy. But we also understand that the appellate process often starts well before an appeal is ever filed. Our appellate attorneys are creative legal thinkers and skilled writers who work with trial teams to develop legal strategies, draft winning briefs, and properly preserve issues for appeal.
Appellate experience across European, German, UK, and U.S. venues
Our success derives not only from our vast technical expertise, but also our extensive appellate experience across European, German, UK, and U.S. courts. For example, Finnegan attorneys have briefed and argued hundreds of patent cases before the U.S. Court of Appeals for the Federal Circuit—quite possibly more than any other law firm—and approximately 40 have served as judicial law clerks to judges on the Federal Circuit or its predecessor court. Finnegan has also represented both petitioners and respondents before the U.S. Supreme Court and regularly assists amici curiae in filing briefs at both the certiorari and merits stages. Our attorneys have participated in briefing more than 50 cases, and they have argued several cases before the Court, including the landmark cases Bilski v. Kappos and Bonito Boats v. Thunder Craft Boats. Whether at these highest courts in the United States or at the Federal Court of Justice in Germany, we bring attorneys who understand what’s at stake and will develop a strategy to meet your needs.
Partners in advancing business goals and market value
Protecting and promoting innovation and market trust is a foundational tenet for Finnegan. Through maintaining a culture of service and leadership in professional bar and legal associations, we collaborate with colleagues in industry and government in promoting IP rights and high professional standards. Organizations we are involved with include American Intellectual Property Law Association (AIPLA), Federal Bar Association (FBA), Federal Circuit Bar Association (FCBA), and Intellectual Property Owners Association (IPO).
Patent Trial and Appeal Board (PTAB) decisions are appealed directly to the US Court of Appeals for the Federal Circuit, where Finnegan attorneys have briefed and argued hundreds of cases.
Appeals require meticulous attention to the details involved and demand a thorough understanding of appellate law to identify the one or two arguments with the most promise to persuade.
Patent opposition or revocation procedures offer third parties an opportunity to attack a European or German patent within a limited time after grant.
Obtained a $240 million jury verdict for client Promptu in a patent infringement lawsuit against Comcast. The jury found that Comcast willfully infringed Promptu’s patents covering voice recognition technology for TV.
2:16-cv-06516, E.D. Pa., Judge Sanchez
22-1939, Fed. Cir., Judges Prost, Moore, Taranto
Obtained complete victory against Carrum on appeal of the District of Delaware’s claim construction to the Federal Circuit following Carrum’s stipulation of non-infringement under the claim construction, thereby exonerating BMW’s ACC system, first sold in 2000, against Carrum’s 2004 patents. Invalidated several asserted claims through post-grant efforts before the U.S. Patent Office, including IPRs and EPRs, and pursued claims through proceedings before the Eastern District of Virginia to vindicate BMW’s patent challenges.
1:18-cv-01645, D. Del., Judge Andrews
21-1435, 24-1480, Fed. Cir., Judges Clevenger, Cunningham, Lourie, Moore, Prost, Taranto
IPR2019-00902, -00903, -00904, -00905, -00927, 00928, PTAB, Judges Browne, Scanlon, Tornquist
90/019,010, CRU
Finnegan represented Bausch & Lomb’s licensee Eye Therapies, LLC in an appeal at the U.S. Court of Appeals for the Federal Circuit from a Patent Trial and Appeal Board (PTAB) decision finding Eye Therapies’ patent directed to a low-dose brimonidine treatment for eye redness (Lumify®) to be unpatentable. In a precedential decision, the Federal Circuit agreed with Finnegan’s arguments and found that the Board had wrongly invalidated the patent based on an incorrect claim construction, vacating and remanding the case back to the PTAB. The proceeding settled shortly thereafter
23-2173, Fed. Cir., Judges Taranto, Stoll, Scarsi
Secured a significant victory for client US Synthetic Corporation (USS) with a precedential decision from the U.S. Court of Appeals for the Federal Circuit (CAFC) overturning an unfavorable 35 U.S.C. § 101 eligibility ruling from the International Trade Commission (ITC).
23-1217, Fed. Cir., Judges Chen, Dyk, Stoll
Secured a covenant-not-to-sue and zero-dollar walkaway for BMW Group in a declaratory judgment action, concluding Arigna’s high-profile patent enforcement campaign involving current amplification technology. This outcome follows a decisive ITC victory, the dismissal of parallel District Court litigation, and multiple concurrent patent office challenges pending at the time of resolution.
1:23-cv-01190, D.D.C., Judge Contreras
2:21-cv-00173, E.D. Tex.
IPR2021-01531, PTAB, Judges Baer, Fenick, Iftikhar
23-1931, Fed. Cir.
90/019,261, USPTO
In a rare rehearing proceeding, successfully represented petitioner Incyte in an inter partes review (IPR) challenging the validity of Concert’s patent before the Patent Trial and Appeal Board (PTAB). Continued representation of appellee Incyte before the Federal Circuit and secured a unanimous affirmance of the PTAB’s obviousness determination.
IPR2017-01256, PTAB, Judges Fitzpatrick, Hulse, Yang, Smith, Franklin
19-2011, Fed. Cir., Judges Hughs, Linn, Stark
Federal Circuit IP Blog
July 8, 2026
Federal Circuit IP Blog
July 8, 2026
Federal Circuit IP Blog
June 26, 2026
Federal Circuit IP Blog
June 26, 2026
Award/Ranking
June 5, 2026
Press Release
April 20, 2026
Award/Ranking
April 10, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.